Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clifton E Barry

Showing results (1-10 of 264) with videos related to

Pageof 27
Sort By:
The New England Journal of Medicine|June 5, 2009
Unorthodox approach to the development of a new antituberculosis therapyClifton E Barry
ACS Central Science|November 3, 2015
Major Global Killer Tamed by HydrogenClifton E Barry
The Journal of Experimental Medicine|March 19, 2009
Clifton E. Barry, III: TB's strategic opponent. Interviewed by Amy MaxmenClifton E Barry
Nature|February 28, 2014
Tuberculosis: Drug discovery goes au naturelClifton E Barry
ACS Infectious Diseases|September 14, 2016
The Death of the "Three Ms"Clifton E Barry
Current Topics in Medicinal Chemistry|March 16, 2011
Lessons from seven decades of antituberculosis drug discoveryClifton E Barry
Nature Medicine|March 6, 2015
Timing is everything for compassionate use of delamanidClifton E Barry
Current Opinion in Microbiology|September 29, 2004
Prospects for new antitubercular drugsKen Duncan, Clifton E Barry
Nature Chemical Biology|January 13, 2006
Getting the iron outClifton E Barry, Helena Boshoff
Current Clinical Pharmacology|February 17, 2010
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosisVéronique Dartois, Clifton E Barry
Pageof 27

Showing results (1-10 of 264) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|June 5, 2009
Unorthodox approach to the development of a new antituberculosis therapyClifton E Barry
ACS Central Science|November 3, 2015
Major Global Killer Tamed by HydrogenClifton E Barry
The Journal of Experimental Medicine|March 19, 2009
Clifton E. Barry, III: TB's strategic opponent. Interviewed by Amy MaxmenClifton E Barry
Nature|February 28, 2014
Tuberculosis: Drug discovery goes au naturelClifton E Barry
ACS Infectious Diseases|September 14, 2016
The Death of the "Three Ms"Clifton E Barry
Current Topics in Medicinal Chemistry|March 16, 2011
Lessons from seven decades of antituberculosis drug discoveryClifton E Barry
Nature Medicine|March 6, 2015
Timing is everything for compassionate use of delamanidClifton E Barry
Current Opinion in Microbiology|September 29, 2004
Prospects for new antitubercular drugsKen Duncan, Clifton E Barry
Nature Chemical Biology|January 13, 2006
Getting the iron outClifton E Barry, Helena Boshoff
Current Clinical Pharmacology|February 17, 2010
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosisVéronique Dartois, Clifton E Barry
Pageof 27